Loading
A phase 2 trial of carboplatin, docetaxel, doxorubicin, cyclophosphamide and other drugs in triple-negative breast cancer, run by University of Kansas Medical Center, not yet recruiting.
Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC is a phase 2, interventional study registered as NCT07743632 by University of Kansas Medical Center, with a registry enrolment figure of 110 participants, started 2026-09 and due to reach its primary completion in 2032-12. Interventions recorded: Carboplatin; Docetaxel; Doxorubicin; Cyclophosphamide; Ivonescimab. Conditions listed: Breast Cancer; Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Histologically confirmed cT1c-T3 N0 or cT1-T3 N1-N2 triple-negative breast cancer". No results are recorded here; the registry entry is the source.
Shares Ivonescimab, Docetaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Ivonescimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Docetaxel, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.